Baxter acquiring gene-therapy firm

Share this article:

Almost a week after announcing Baxter was going to break into two divisions, the Illinois company is already expanding.

Crain's Chicago Business reports that the company is buying up partner Chatham Therapeutics for $70 million.

Crain's notes that the $70-million deal may not be an all-in-one payment and that Baxter may provide the gene therapy company milestone payments even after the purchase.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.